Philippe Hammel
Geneve, GE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma.
Journal: Cancer immunology research
Published: December 27, 2023
A quantitative comparison of antibodies against epitope tags for immunofluorescence detection.
Journal: FEBS open bio
Published: May 30, 2023
Targeting OLFML3 in Colorectal Cancer Suppresses Tumor Growth and Angiogenesis, and Increases the Efficacy of Anti-PD1 Based Immunotherapy.
Journal: Cancers
Published: July 29, 2021
Intracellular targeting of Cisd2/Miner1 to the endoplasmic reticulum.
Journal: BMC molecular and cell biology
Published: February 19, 2021
Generation of Monoclonal Antibodies Specific for Native LL37 and Citrullinated LL37 That Discriminate the Two LL37 Forms in the Skin and Circulation of Cutaneous/Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients.
Journal: Antibodies (Basel, Switzerland)
Published: April 05, 2020
A recombinant antibody toolbox for Dictyostelium discoideum.
Journal: BMC research notes
Published: March 04, 2020
Biodegradable and plasma-treated electrospun scaffolds coated with recombinant Olfactomedin-like 3 for accelerating wound healing and tissue regeneration.
Journal: Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
Published: May 09, 2016
Targeting olfactomedin-like 3 inhibits tumor growth by impairing angiogenesis and pericyte coverage.
Targeting olfactomedin-like 3 inhibits tumor growth by impairing angiogenesis and pericyte coverage.
Journal: Molecular cancer therapeutics
Published: September 25, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026